NCT02916251View on ClinicalTrials.gov

ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

December 1, 2016

Primary Completion Date

April 5, 2017

Study Completion Date

April 5, 2017

Conditions
Diabetes Mellitus Type 1
Interventions
DRUG

ZP4207(dasiglucagon) glucagon analogue

Cross-over design with single s.c. administration in euglycemic and hypoglycemic T1D

DRUG

Glucagon (Native glucagon)

Cross-over design with single s.c. administration in euglycemic T1D

Trial Locations (1)

41460

Profil Institut für Stoffwechselforschung GmbH, Neuss

Sponsors

Lead Sponsor

Zealand Pharma
All Listed Sponsors
lead

Zealand Pharma

INDUSTRY